A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Swift Biosciences and BillionToOne Partner Together for Commercialization and Manufacturing of EUA Approved COVID-19 Test

September 29, 2020

Swift Biosciences, a leader in Next-Generation Sequencing Manufacturing & Technology and BillionToOne, a precision diagnostics company today announced that Swift Bioscience will be the exclusive distributor of BillionToOne’s RNA extraction-free, Emergency Use Authorization (EUA) COVID-19 Test Kit for high capacity testing of up to a million tests per day. The test is designed to detect the virus that causes COVID-19 in respiratory specimens obtained from nasal swabs, nasopharyngeal swabs, or oropharyngeal swabs.

Swift Biosciences notes: The BillionToOne COVID-19 test uses different sets of instruments and chemicals from existing COVID-19 tests, enabling labs to unlock a new set of unused capacity. The BillionToOne test sequences the virus’ genome – making the test sensitive, specific, and accurate compared to other COVID-19 tests on the market.  Most notable, this test does not require RNA extraction which is costly, time-consuming, and critical supply chain demands due to flu season will not negatively affect this workflow.  Additionally, the test is easily adaptable for any clinical labs with Sanger Sequencers and requires minimal training.

BillionToOne approached Swift Biosciences in April of 2020 and asked for their assistance to manufacture and provide quality assurance shipping and logistics.  Swift has provided BillionToOne with 60,000 RUO reactions that have been adopted by DASA, the biggest medical diagnostics laboratory in Brazil.  With the EUA approval from the U.S. Food and Drug Administration (FDA), Swift will be leading all worldwide commercial efforts, except for Brazil.

“Early in the pandemic, Swift was quick to pivot and offer products for sequencing the SARS-CoV-2 genome and associated receptors like ACE2.  By including the BillionToOne’s COVID Diagnostic Test Kit into Swift’s product portfolio, it allows us the opportunity to provide the full complement of tools to assist in the fight against COVID-19 in ways that were not possible before.  Clinical laboratories can use their excess Sanger instruments to full capacity to do over 3,000 test per day per instrument,” said Nathan Wood, CEO of Swift Biosciences.

The BilliontoOne qSanger-COVID-19 Assay is available for immediate purchase, and shipment through SwiftBioSci.com for North America and Swift’s global distribution network.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy